Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Procyclidine hydrochloride
122
CHF
CHF 122.00
In stock
CDX-P0608-G0011 gCHF 122.00
CDX-P0608-G0055 gCHF 489.00
| Product Details | |
|---|---|
| Synonyms | α-Cyclohexyl-α-phenyl-1-pyrrolidinepropanol; Arpicolin; Tricyclamol hydrochloride |
| Product Type | Chemical |
| Properties | |
| Formula |
C19H29NO . HCl |
| MW | 323.9 |
| CAS | 1508-76-5 |
| RTECS | UY1926000 |
| Purity Chemicals | ≥98% (TLC) |
| Appearance | White to off-white powder. |
| Solubility | Soluble in DMOS, DMF, ethanol (all 1mg/ml) or chloroform. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | ZFSPFXJSEHCTTR-UHFFFAOYSA-N |
| Smiles | OC(C1CCCCC1)(CCN2CCCC2)C3=CC=CC=C3.Cl |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +20°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at RT. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Procyclidine is a synthetic anticholinergic agent and atropine-like antispasmodic. It exhibits therapeutic effects against parkinson′s disease and schizophrenia. Procyclidine is an antagonist of muscarinic acetylcholine receptors (Kis = 4.47, 42.66, 7.24, 6.03, and 4.79 nM for M1-5 receptors, respectively). It also affects N-methyl-D-aspartate (NMDA) glutamine and nicotinic acetylcholine receptors to a lower extent.
Product References
(1) R.B. Barlow, et al.; Br. J. Pharmacol. 72, 277 (1981) | (2) M. Waelbroeck, et al.; Eur. J. Pharmacol. 189, 135 (1990) | (3) S. Lazareno, et al.; Mol. Pharmacol. 38, 805 (1990) | (4) T. Zarnowski, et al.; J. Neural. Transm. Gen. Sect. 97, 1 (1994) | (5) M.L. Sipos, et al.; Psychopharmacol. 147, 250 (1999) | (6) V. Jevtovic-Todorovic, et al.; Neuropharmacol. 44, 739 (2003) | (7) R. Roesler, et al.; J. Clin. Psychopharmacol. 23, 666 (2003)